124 related articles for article (PubMed ID: 26009261)
1. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
[TBL] [Abstract][Full Text] [Related]
3. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
[TBL] [Abstract][Full Text] [Related]
4. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Bouabdallah K; Furst S; Asselineau J; Chevalier P; Tournilhac O; Ceballos P; Vigouroux S; Tabrizi R; Doussau A; Bouabdallah R; Mohty M; Le Gouill S; Blaise D; Milpied N
Ann Oncol; 2015 Jan; 26(1):193-198. PubMed ID: 25361987
[TBL] [Abstract][Full Text] [Related]
5. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis.
Wei J; Xu J; Cao Y; Zhou J; Zhang Y
Acta Haematol; 2015; 133(2):136-44. PubMed ID: 25247746
[TBL] [Abstract][Full Text] [Related]
7. Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression.
Morsink LM; Hazenberg CLE; Choi G; de Groot MR; Biswana A; Bellido M; Kooistra HAM; Bungener LB; Meijer K; Mulder AB; Huls G
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38740138
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
Eyre TA; Caillard S; Finel H; Boumendil A; Kothari J; Zimmermann H; Trappe RU; De Wilde V; Tholouli E; Kanfer E; Broom A; Damaj G; Bargetzi M; Kozák T; Hilgendorf I; Crawley C; Kerre T; Trněný M; Bachy E; Robinson S; Montoto S
Bone Marrow Transplant; 2021 Sep; 56(9):2118-2124. PubMed ID: 33864020
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.
Menzel H; Hinmüller K; Kolb HJ; Schuster T; Hoellein A; Peschel C; Dechow T; Keller U
Ther Adv Hematol; 2012 Apr; 3(2):81-8. PubMed ID: 23556114
[TBL] [Abstract][Full Text] [Related]
11. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party.
Penack O; Tridello G; Salmenniemi U; Martino R; Khanna N; Perruccio K; Fagioli F; Richert-Przygonska M; Labussière-Wallet H; Maertens J; Jubert C; Aljurf M; Pichler H; Kriván G; Kunadt D; Popova M; Gabriel M; Calore E; Blau IW; Benedetti F; Itäla-Remes M; de Kort E; Russo D; Faraci M; Ménard AL; Borne PVD; Poiré X; Yesilipek A; Gozdzik J; Yeğin ZA; Yañez L; Facchini L; Van Gorkom G; Thurner L; Kocak U; Sampol A; Zuckerman T; Bierings M; Mielke S; Ciceri F; Wendel L; Knelange N; Mikulska M; Averbuch D; Styczynski J; Camara R; Cesaro S
EClinicalMedicine; 2024 Jan; 67():102393. PubMed ID: 38152413
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.
Sidana S; Dueck AC; Thanarajasingam G; Griffin JM; Thompson C; Durani U; Burtis M; Warsame R; Paludo J; Gertz MA; Dispenzieri A; Ansell SM; Rajkumar SV; Yost K; Bennani N; Lin Y; Kumar S
Transplant Cell Ther; 2022 Aug; 28(8):473-482. PubMed ID: 35550440
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?
Gahrton G; Iacobelli S; Garderet L; Yakoub-Agha I; Schönland S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32664274
[TBL] [Abstract][Full Text] [Related]
14. Study of clinical characteristics, risk factors and outcomes for tuberculosis post allogeneic stem cell transplant: never count it out.
Kapoor J; Mirgh SP; Khushoo V; Mehta P; Ahmed R; Bansal N; Bhurani D; Agrawal N
Ther Adv Infect Dis; 2021; 8():20499361211008674. PubMed ID: 33912346
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV.
Rubinstein PG; Galvez C; Ambinder RF
Curr Opin Infect Dis; 2024 Jun; ():. PubMed ID: 38820072
[TBL] [Abstract][Full Text] [Related]
16. EASIX-1year and late mortality after allogeneic stem cell transplantation.
Kordelas L; Terzer T; Gooley T; Davis C; Sandmaier BM; Sorror M; Penack O; Schaeper NDE; Blau IW; Beelen D; Radujkovic A; Dreger P; Luft T
Blood Adv; 2023 Sep; 7(18):5374-5381. PubMed ID: 37477588
[TBL] [Abstract][Full Text] [Related]
17. Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival.
Auberle C; Lenihan D; Gao F; Cashen A
Cardiooncology; 2023 Jan; 9(1):1. PubMed ID: 36604733
[TBL] [Abstract][Full Text] [Related]
18. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
19. Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors.
Bradstock K; Bilmon I; Kwan J; Blyth E; Micklethwaite K; Huang G; Deren S; Byth K; Gottlieb D
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1641-5. PubMed ID: 26079442
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.
Mossoba ME; Halverson DC; Kurlander R; Schuver BB; Carpenter A; Hansen B; Steinberg SM; Ali SA; Tageja N; Hakim FT; Gea-Banacloche J; Sportes C; Hardy NM; Hickstein DD; Pavletic SZ; Khuu H; Sabatini M; Stroncek D; Levine BL; June CH; Mariotti J; Rixe O; Fojo AT; Bishop MR; Gress RE; Fowler DH
Clin Cancer Res; 2015 Oct; 21(19):4312-20. PubMed ID: 26071480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
